

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
MB Number:	3235-0287
stimated average burden hours per	
sponse	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)	*										L	EDIC II ED C D (\ . T			
					Issuer Name and Ticker or Trading Symbol MA Corp [XOMA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner				
667 MADISON AVENUE	E, 21ST FLOOR	(I	fiddle)	3. Date of E 08/19/201	f Earliest Transaction (Month/Day/Year) 013						-	Officer (give title below)		Other (specify below)		
	(Street)			08/21/2013								6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person				
NEW YORK, NY US 100 (City)	65 (State)		(Zip)													
	(State)											ed, Disposed of, or Beneficially Ow				
1. Title of Security (Instr. 3)		2. Transacti (Month/Day	y/Year) E	2A. Deemed Execution Date, if any	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)				Beneficial		
				(I	Month/Da	y/Year)	Code	V	Amount	(A) or (D)	Price				Direct (D) or Indirect (I) (Instr. 4)	
Common Stock			08/19/20	13			P		882,323	A	\$ 3.62	2,829,753			I	See footnote (1) (4) (5)
Common Stock			08/19/20	13			P		1,854,058	A	\$ 3.62	19,767,770			I	See footnote (2) (4) (5)
Common Stock			08/19/20	13			P		21,410	A	\$ 3.62	510,449			I	See footnote (3) (4) (5)
Reminder: Report on a separate l	ine for each class of	securities beneficially	owned directly or i	ndirectly.			•	•							•	•
		,										information contained in this for ntly valid OMB control number.	orm are not re	equired to	SEC	2 1474 (9-02)
				Table			curities Acquire				ı					
Title of Derivative Security	2. Conversion or	3. Transaction Date	3A. Deemed	4 Tranca		<u> </u>	ls, warrants, opt Number of Deriva		6. Date Exer		7 Title	and Amount of Underlying	8. Price of	9. Number of	10.	11. Nature
(Instr. 3)	Exercise Price of Derivative Security	of (Month/Day/Year) Ex	Execution Date, if any (Month/Day/Year)	(Instr. 8)	str. 8) Sec Dis		number of Derivative curities Acquired (A) or sposed of (D) str. 3, 4, and 5)		Expiration Date Secu		Securit			Derivative Securities Beneficially	Ownership Form of Derivative	of Indirect Beneficial Ownership
				Cod		v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Owned Following Reported Transaction(: (Instr. 4)	Security: Direct (D) or Indirect (I) (Instr. 4)	(Instr. 4)

	Relationships							
Reporting Owner Name / Address		10% Owner	Officer	Other				
BAKER BROS. ADVISORS LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X						
667, L.P. 667 MADISON AVENUE 21ST FLOOR NEW YORK, NY US 10065	X	X						
Baker Brothers Life Sciences LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X						
14159, L.P. 667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X						
Baker Bros. Advisors (GP) LLC 667 MADISION AVENUE 21ST FLOOR NEW YORK, NY US 10065	х	X						
BAKER FELIX 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X						
BAKER JULIAN 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	Х						

Signatures

By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing Title: President /s/ Scott L. Lessing						
"Signature of Reporting Person	Date					
Baker Bros. Advisors, LLC, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing	08/21/2013					
"Signature of Reporting Person	Date					
Baker Bros. Advisors, LLC, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P Name:Scott L. Lessing, Title: President /s/	08/21/2013 Date					
Baker Bros. Advisors, LLC, Mgmt. Co. and Inv. Adviser to 14159, L.P., pursuant to authority granted by 14159 Capital, L.P., GP to 14159, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing	08/21/2013					
Signature of Reporting Person	Date					
Name: Scott L. Lessing Title: President /s/ Scott L. Lessing	08/21/2013					
**Signature of Reporting Person	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 2,829,753 shares of Common Stock of the Issuer beneficially owned by 667, L.P., a limited partnership of which the sol Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667, L.P.
- (2) As a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 19,767,770 shares of Common Stock of the Issuer beneficially owned by Baker Brothers Life Sciences, L partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Baker Brothers Life Sciences, L.P.
- (3) As a result of their ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 510,449 shares of Common Stock of the Issuer beneficially owned by 14159, L.P., a limited partnership of which the sole general 14159 Capital L.P.'s right to receive an allocation of a portion of the profits from 14159, L.P.
- (4) The aggregate indirect beneficial ownership reported on this form is 23,107,972 shares.
- Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to 667, L.P., Baker Brothers Life Sciences, L.P. and 14159, L.P. (the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer at (5) sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds relinquished t Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser of th

Remarks:

This amended Form 4 is being filed to properly reflect that the acquisitions in Table I were non-exempt purchases.

Kelvin Neu, a Managing Director of Baker Bros. Advisors, LLC, is a director of Xoma Corporation (the "Issuer"). By virtue of his representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchan

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.